Toggle navigation
World Orphan Drug Congress USA 2024
23 - 25 April
Boston Convention and Exhibition Center,
Boston, MA
register now
home
our story
event photos
video
LinkedIn
X
Facebook
Sponsors & Exhibitors
Partners
Download Prospectus
Apply to Sponsor
Start-Ups
Poster Sessions
agenda
advocacy support seminars
early access program seminars
patient data seminars
workshops
keynotes
advanced therapies
advanced therapies clinical development
AI & digital health
commercial
clinical development & regulatory
diagnosis
drug discovery
global market access
pitch & partner
policy
pricing & reimbursement
rare disease advocacy world
rare oncology
roundtables
Conference
Speakers
Patient Advocacy Groups
Apply to Speak
networking
accommodation
event info
times & location
event app
register
Commercial
Commercial, Wednesday 24 April 2024
Commercial
11:24
Chair's Remarks
Afshan Rizvi Hussain,
Managing Director, Global Rare Disease Lead,
Havas Health
Commercial
11:25
NIH as your technology development and commercialization partner
Michael Salgaller,
Supervisor, Technology Analysis and Marketing Unit (TAMU),
National Institute of Health (NIH)
Commercial
11:45
Health Technology Assessment of rare disease drugs: Exploring willingness to pay
Lindy Forte,
Senior Vice President, Market Access and Pricing,
EVERSANA
Commercial
12:05
Building commercial teams for a successful pre-launch
Moderator:
Kevin Baruzzi,
Partner,
Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Wills Hughes-Wilson,
Chief Patient Access & Commercial Planning,
Mereo Biopharma
Ron Cooper,
Former CEO,
Albireo Pharma
Jason Tardio,
Chief Operating Officer,
Ovid Therapeutics
×
Day 1 - World Orphan Drug Congress USA 2024 12:05, Commercial
Building commercial teams for a successful pre-launch
Moderator:
Kevin Baruzzi,
Partner,
Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Wills Hughes-Wilson,
Chief Patient Access & Commercial Planning,
Mereo Biopharma
Ron Cooper,
Former CEO,
Albireo Pharma
Jason Tardio,
Chief Operating Officer,
Ovid Therapeutics
Commercial
12:45
Patient engagement strategy earlier in commercial planning
Melissa Williams,
Founder,
Simply Patient
Commercial
13:05
Meet the moment for advanced therapies: Past learnings, present state and collaborating for the future
Michael Lehmicke,
Senior Vice President of Science and Industry Affairs,
Alliance for Regenerative Medicine
Shaun Ellis,
Vice President, Global Market Access Specialty Ophthalmology,
Johnson & Johnson
×
Day 1 - World Orphan Drug Congress USA 2024 13:05, Commercial
Meet the moment for advanced therapies: Past learnings, present state and collaborating for the future
Michael Lehmicke,
Senior Vice President of Science and Industry Affairs,
Alliance for Regenerative Medicine
Shaun Ellis,
Vice President, Global Market Access Specialty Ophthalmology,
Johnson & Johnson
Commercial
14:59
Chair's Remarks
Afshan Rizvi Hussain,
Managing Director, Global Rare Disease Lead,
Havas Health
Commercial
15:00
Use of machine learning to improve time to diagnosis of patients with probable MPS II: A case study
Ramaa Nathan,
VP of Data Science and Real-World Evidence,
EVERSANA
Pierantonio Russo, FCCP, FAAP, STS,
Corporate Chief Medical Officer,
EVERSANA
×
Day 1 - World Orphan Drug Congress USA 2024 15:00, Commercial
Use of machine learning to improve time to diagnosis of patients with probable MPS II: A case study
Ramaa Nathan,
VP of Data Science and Real-World Evidence,
EVERSANA
Pierantonio Russo, FCCP, FAAP, STS,
Corporate Chief Medical Officer,
EVERSANA
Commercial
15:20
Commercializing in the ultra-orphan space: Unique challenges and opportunities
Moderator:
Kristin Marvin-Keller,
Managing Director,
Havas Life Rare
Amanda Cali,
Trustee,The Radiant Hope Foundation; Trustee,Ian Cali FOP Research Fund at University of PA; Co-Founder/Officer,
Tin Soldiers Global
Lisa Jordan,
Senior Vice President, Management Supervisor,
Havas Life Rare
Zayd Daruwala,
VP, Medical Strategy,
Havas Life Rare
Jessica Klein,
Rare Disease Awareness Marketer,
KnoJAK Consulting
×
Day 1 - World Orphan Drug Congress USA 2024 15:20, Commercial
Commercializing in the ultra-orphan space: Unique challenges and opportunities
Moderator:
Kristin Marvin-Keller,
Managing Director,
Havas Life Rare
Amanda Cali,
Trustee,The Radiant Hope Foundation; Trustee,Ian Cali FOP Research Fund at University of PA; Co-Founder/Officer,
Tin Soldiers Global
Lisa Jordan,
Senior Vice President, Management Supervisor,
Havas Life Rare
Zayd Daruwala,
VP, Medical Strategy,
Havas Life Rare
Jessica Klein,
Rare Disease Awareness Marketer,
KnoJAK Consulting
Commercial
16:00
What it takes to order that one test by physicians
Moderator:
Christine Yu,
Chief Executive Officer,
P2P Syncro
Pierantonio Russo, FCCP, FAAP, STS,
Corporate Chief Medical Officer,
EVERSANA
Gay Grossman,
Co-Founder and Patient Advocate,
ADCY5.org
Erik Feingold,
CEO & Co-Founder,
FDNA, Inc
×
Day 1 - World Orphan Drug Congress USA 2024 16:00, Commercial
What it takes to order that one test by physicians
Moderator:
Christine Yu,
Chief Executive Officer,
P2P Syncro
Pierantonio Russo, FCCP, FAAP, STS,
Corporate Chief Medical Officer,
EVERSANA
Gay Grossman,
Co-Founder and Patient Advocate,
ADCY5.org
Erik Feingold,
CEO & Co-Founder,
FDNA, Inc
last published: 25/Apr/24 19:55
BOOK NOW
Commercial, Thursday 25 April 2024
Commercial
11:59
Chair's Remarks
Inderpreet Kambo,
Principal (Partner) - Information Management & Analytics,
IQVIA
Commercial
12:00
Preparing early for ex-US commercialisation – a patient access perspective
Josie Godfrey,
Co-Founder and Chief Executive Officer,
Realise Advocacy
Commercial
12:20
AI, insights and technology transformations within rare diseases
Inderpreet Kambo,
Principal (Partner) - Information Management & Analytics,
IQVIA
Commercial
12:40
Transformative launch strategies: Commercializing orphan products for success
Moderator:
Simone Seiter,
Senior Partner,
Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Tsveta Milanova,
Chief Commercial Officer,
Agios Pharmaceuticals
Neha Kumar,
Global Commercial Strategy - Precision Medicine,
Johnson & Johnson Innovative Medicine
Grant Castor,
SVP Commercial Strategy & Operations,
Sentynl Therapeutics
×
Day 2 - World Orphan Drug Congress USA 2024 12:40, Commercial
Transformative launch strategies: Commercializing orphan products for success
Moderator:
Simone Seiter,
Senior Partner,
Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Tsveta Milanova,
Chief Commercial Officer,
Agios Pharmaceuticals
Neha Kumar,
Global Commercial Strategy - Precision Medicine,
Johnson & Johnson Innovative Medicine
Grant Castor,
SVP Commercial Strategy & Operations,
Sentynl Therapeutics
Commercial
13:20
Rescuing ‘orphaned’ drug programs & creating a viable commercial pathway for ultra-rare disease treatments
Craig Martin,
President, Rithm Health; CEO,
Orphan Therapeutics Accelerator
last published: 25/Apr/24 19:55
BOOK NOW
Get Involved At
World Orphan Drug Congress USA
To Sponsor Or Exhibit
Justin Franks
justin.franks@terrapinn.com
t/ +1 914 819 3506
To Speak
Gina McHugh
gina.mchugh@terrapinn.com
t/ +1 646 619 1775
Marketing & Press Opportunities
Kaylie Brogan
kaylie.brogan@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events
good conduct policy
anti-slavery policy
anti-money laundering & financial crime policy
diversity & inclusion policy
sustainability policy
sanctions policy
© Terrapinn Holdings Ltd. MMXXIII
privacy
general t&c's
contact
subscription preferences
brochure